Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Jindi Han"'
Autor:
Xiangjuan Ma, Ziran Zhang, Xiaoling Chen, Jie Zhang, Jun Nie, Ling Da, Weiheng Hu, Guangming Tian, Di Wu, Jindi Han, Sen Han, Jieran Long, Yang Wang, Jian Fang
Publikováno v:
Thoracic Cancer, Vol 12, Iss 12, Pp 1841-1850 (2021)
Abstract Background Small cell lung cancer (SCLC) is characterized by aggressive spread and poor prognosis, but has limited treatment options. Results of prognostic factors from randomized trials on treatment arrangement are conflicting and large‐s
Externí odkaz:
https://doaj.org/article/eba69f95fa38422da4d3181c6d7446ec
Autor:
Jie Zhang PhD, Di Wu PhD, Ziran Zhang PhD, Jieran Long PhD, Guangming Tian PhD, Yang Wang PhD, Xiangjuan Ma PhD, Xiaoling Chen PhD, Jindi Han PhD, Weiheng Hu PhD, Ling Dai PhD, Jun Nie PhD, Jian Fang PhD
Publikováno v:
Technology in Cancer Research & Treatment, Vol 20 (2021)
Objective: Pembrolizumab and bevacizumab both have antitumor activity. According to NCCN updated guideline the benefit of pembrolizumab or bevacizumab as a first line in management of advanced nonsmall cell lung cancer (NSCLC) is documented in random
Externí odkaz:
https://doaj.org/article/31934071c47149bf87053edf3807d5a3
Autor:
Di Wu, Jun Nie, Ling Dai, Weiheng Hu, Jie Zhang, Xiaoling Chen, Xiangjuan Ma, Guangming Tian, Jindi Han, Sen Han, Jieran Long, Yang Wang, Ziran Zhang, Jian Fang
Publikováno v:
Thoracic Cancer, Vol 10, Iss 7, Pp 1590-1596 (2019)
Background This real‐world study assessed the efficacy and toxicity of anlotinib as salvage treatment in Chinese patients with advanced non‐small cell lung cancer (NSCLC). Methods The medical records of 81 patients with advanced NSCLC who had fai
Externí odkaz:
https://doaj.org/article/056f8498d2aa4d4c81185921e619bab5
Autor:
Yang Wang, Jun Nie, Ling Dai, Weiheng Hu, Xiaoling Chen, Jindi Han, Xiangjuan Ma, Guangming Tian, Sen Han, Jieran Long, Ziran Zhang, Jian Fang
Publikováno v:
Thoracic Cancer, Vol 10, Iss 1, Pp 17-23 (2019)
Background Thymoma and thymic carcinoma are rare thymic epithelial tumors. We investigated the efficacy of first‐line gemcitabine and cisplatin (GP) chemotherapy versus gemcitabine and cisplatin chemotherapy combined with the anti‐angiogenic drug
Externí odkaz:
https://doaj.org/article/97aa73763f3e4c0db10a54176f882449
Autor:
Xiaoling Chen, Jun Nie, Ling Dai, Weiheng Hu, Jie Zhang, Jindi Han, Xiangjuan Ma, Guangming Tian, Sen Han, Di Wu, Yang Wang, Jieran Long, Ziran Zhang, Jian Fang
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundProgrammed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) inhibitors are increasingly used in China, but no real-world data are available about the immune-related adverse events (irAEs). This real-world retrospective study aimed t
Externí odkaz:
https://doaj.org/article/ac8c87737a594bacabed245b3320498d
Autor:
Meizhen Tang, Jie Jiang, Qilin Lv, Bin Yang, Mingna Zheng, Xin Gao, Jindi Han, Yingjie Zhang, Yuewei Yang
Publikováno v:
Royal Society Open Science, Vol 7, Iss 3 (2020)
Improving the effect of microbial denitrification under low-temperature conditions has been a popular focus of research in recent years. In this study, graphene oxide (GO)-modified polyvinyl-alcohol (PVA) and sodium alginate (SA) (GO/PVA–SA) gel be
Externí odkaz:
https://doaj.org/article/fbb620c8bcc74714bdfa5b2dc9f436a8
Autor:
Yang WANG, Jian FANG, Jun NIE, Ling DAI, Weiheng HU, Jie ZHANG, Xiangjuan MA, Jindi HAN, Xiaoling CHEN, Guangming TIAN, Di WU, Sen HAN, Jieran LONG
Publikováno v:
Chinese Journal of Lung Cancer, Vol 19, Iss 8, Pp 508-514 (2016)
Background and objective Radiotherapy combined with chemotherapy or molecular targeted therapy remains the standard of treatment for brain metastases from non-small cell lung cancer (NSCLC). The aim of this study is to determine if the deferral of br
Externí odkaz:
https://doaj.org/article/c4630914c19f493f8f23d2f49d653615
Autor:
Di WU, Jian FANG, Jun NIE, Ling DAI, Xiaoling CHEN, Jie ZHANG, Weiheng HU, Jindi HAN, Xiangjuan MA, Guangming TIAN, Sen HAN, Jieran LONG, Yang WANG
Publikováno v:
Chinese Journal of Lung Cancer, Vol 18, Iss 5, Pp 272-279 (2015)
Background and objective Chemotherapy is a highly efficient primary treatment for extensive-stage small cell lung cancer (ES-SCLC). However, patients receiving such treatment are prone to develop drug resistance. Local treatment is palliative and thu
Externí odkaz:
https://doaj.org/article/4056fd667f594ba9b545292d24635e43
Autor:
Xiaoling CHEN, Jian FANG, Jun NIE, Ling DAI, Jie ZHANG, Weiheng HU, Jindi HAN, Xiangjuan MA, Guangming TIAN, Sen HAN, Di WU, Jieran LONG, Yang WANG
Publikováno v:
Chinese Journal of Lung Cancer, Vol 17, Iss 1, Pp 15-23 (2014)
Background and objective Lung cancer is currently the leading cause of cancer death, two thirds of patients are over the age of 65. Small cell lung cancer (SCLC) accounts for about 15%-20% of all lung cancer. The objective of this study is to evaluat
Externí odkaz:
https://doaj.org/article/daead9202c234b269aa4379327f23427
Autor:
Ling DAI, Jian FANG, Jun NIE, Weiheng HU, Xiaoling CHEN, Jindi HAN, Guangming TIAN, Sen HAN, Xuyi LIU
Publikováno v:
Chinese Journal of Lung Cancer, Vol 13, Iss 11, Pp 1050-1055 (2010)
Background and objective Some clinical predictors can be used to evaluate the efficacy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for non-small cell lung cancer (NSCLC), including female, East-Asian, non-smoker,
Externí odkaz:
https://doaj.org/article/33ec994b7e634455ad64ca60c1e86cef